argenex (NASDAQ:ARGX) Stock Gets Price Target Reduction from Morgan Stanley

argenex (NASDAQ:ARGX – Free Report) had its price target lowered by Morgan Stanley from $1,190.00 to $1,130.00 in a report published on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

ARGX has been the subject of a number of other research reports. The Goldman Sachs Group reiterated a “buy” rating on shares of argenex in a research report on Friday, September 25th. Truist Financial boosted their price target on shares of argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. HC Wainwright boosted their price target on shares of argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Wedbush dropped their price target on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a research note on Thursday, October 8th. Finally, Guggenheim cut their price objective on shares of argenex from $1,185.00 to $1,120.00 and set a “buy” rating for the company in a report on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,155.24.

Read Our Latest Research Report on ARGX

argenex Price Performance

NASDAQ:ARGX opened at $960.04 on Friday. The business has a fifty day simple moving average of $923.87 and a two-hundred day simple moving average of $860.78. argenex has a 1 year low of $661.85 and a 1 year high of $1,072.75. The company has a market capitalization of $60.38 billion, a P/E ratio of 33.50, a P/E/G ratio of 0.89 and a beta of 0.48.

argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The business had revenue of $1.75 billion for the quarter. As a group, analysts anticipate that argenex will post 28.41 earnings per share for the current year.

Institutional Trading of argenex

Institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in shares of argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after buying an additional 83,568 shares in the last quarter. First Trust Advisors LP increased its stake in argenex by 98.9% in the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after acquiring an additional 53,293 shares during the last quarter. Checkpoint Capital L.P. increased its stake in argenex by 38.3% in the 3rd quarter. Checkpoint Capital L.P. now owns 181,500 shares of the company’s stock worth $174,042,000 after acquiring an additional 50,217 shares during the last quarter. Squarepoint Ops LLC increased its stake in argenex by 314.8% in the 2nd quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock worth $54,182,000 after acquiring an additional 44,321 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in shares of argenex by 40.3% in the 3rd quarter. Public Sector Pension Investment Board now owns 118,300 shares of the company’s stock valued at $113,000 after acquiring an additional 34,000 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Company Profile

(Get Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

Further Reading

Analyst Recommendations for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.